Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vitrolife ABCHIX:VITRS 66 3-1 Month Momentum % is -18.32% as of Sep. 06, 2026. GuruFocus rates CHIX:VITRS with a GF Score™ of 66/100 and a GF Value™ of kr135.46 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 845 Medical Devices & Instruments companies, Vitrolife AB ranks worse than 58.7% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-06), Vitrolife AB's 3-1 Month Momentum % is -18.32%.
The industry rank for Vitrolife AB's 3-1 Month Momentum % or its related term are showing as below:
CHIX:VITRs's 3-1 Month Momentum % is ranked worse than 58.7% of 845
companies
in the Medical Devices & Instruments industry
Industry Median: -3.7
vs CHIX:VITRs: -18.32
Vitrolife AB (CHIX:VITRs) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Vitrolife AB 3-1 Month Momentum % Related Terms
CHIX:VITRS vs ABT, SYK, MDT: 3-1 Month Momentum % Comparison
For the Medical Devices subindustry, Vitrolife AB's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitrolife AB 3-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vitrolife AB's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Vitrolife AB's 3-1 Month Momentum % falls into.
Vitrolife AB (CHIX:VITRs) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vitrolife AB (CHIX:VITRS) has a 3-1 Month Momentum % of -18.32% as of Sep. 06, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Vitrolife AB and its competitors. According to the industry distribution chart, Vitrolife AB ranks #496 out of 845 companies in the Medical Devices & Instruments industry, placing it in the top 58.7%.
Is Vitrolife AB's 3-1 Month Momentum % too high?
Vitrolife AB's current 3-1 Month Momentum % is -18.32%. Based on the distribution chart, Vitrolife AB ranks #496 out of 845 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Vitrolife AB has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vitrolife AB's 3-1 Month Momentum % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Vitrolife AB ranks #496 out of 845 companies for 3-1 Month Momentum %. This places Vitrolife AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Devices & Instruments company?
A good 3-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Vitrolife AB and its competitors. Vitrolife AB's current 3-1 Month Momentum % is -18.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrolife AB stock overvalued right now?
Based on GuruFocus' analysis, Vitrolife AB (CHIX:VITRS) is currently considered Possible Value Trap. The stock's GF Value™ is kr135.46, compared to a current price of kr86.38 — trading 36.2% below its estimated fair value. The current 3-1 Month Momentum % is -18.32%. Vitrolife AB's overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Vitrolife AB (CHIX:VITRS), the current 3-1 Month Momentum % is -18.32% as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vitrolife AB (CHIX:VITRS) Overvalued in 2026?
Based on GuruFocus' analysis, Vitrolife AB stock appears to be undervalued.
The current stock price of kr86.38 is trading 36.2% below its estimated GF Value™ of kr135.46.
GuruFocus considers Vitrolife AB to be Possible Value Trap.
Key valuation signals for CHIX:VITRS:
3-1 Month Momentum %: -18.32%
GF Value™: kr135.46 vs. price of kr86.38 (36.2% below fair value)
No single metric tells the full story. See the CHIX:VITRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The company has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.
66GF Score
Get the complete analysis for CHIX:VITRS
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:VITRS has been successfully added to your 
